The World Health Organization's End TB Strategy prioritizes universal access to an early
diagnosis and comprehensive drug susceptibility testing (DST) for all individuals with …

Background Drug-resistant tuberculosis (DR-TB) is considered to be a public health threat
and is difficult to cure, requiring a lengthy treatment with potent, potentially toxic drugs. The …

Background Bedaquiline is a life-saving tuberculosis drug undergoing global scale-up.
People at risk of weak tuberculosis drug regimens are a priority for novel drug access …

Background Bedaquiline and clofazimine are important drugs in the treatment of drug-
resistant tuberculosis and are commonly used across southern Africa, although drug …

Antibiotic resistance among bacterial pathogens poses a major global health threat.
Mycobacterium tuberculosis complex (MTBC) is estimated to have the highest resistance …

Drug-resistant tuberculosis is a serious global health threat. Bedaquiline (BDQ) is a
relatively new core drug, targeting the respiratory chain in Mycobacterium tuberculosis (Mtb) …

Multidrug-resistant (MDR) tuberculosis (TB), resistant to isoniazid and rifampicin, continues
to be one of the most important threats to controlling the TB epidemic. Over the last few …

Methods In June 2018, BDQ and CFZ were added to the second-line phenotypic drug
susceptibility testing (pDST) panel at the National and WHO Supranational Reference …

The role of mutations in genes associated with phenotypic resistance to bedaquiline (BDQ)
and delamanid (DLM) in Mycobacterium tuberculosis complex (MTBc) strains is poorly …

Background Bedaquiline is a crucial drug for control of rifampicin-resistant tuberculosis.
Molecular drug resistance assays could facilitate effective use of bedaquiline and …